Abstract P435: Medical and Neurosurgical Interventions in Left Ventricular Assist Device-Associated Intracranial Hemorrhage

Abstract

Background: Management of intracranial hemorrhage (ICH) in patients with left ventricular assist devices (LVADs) is complicated by the competing concerns of hematoma expansion and the risk of thrombotic events. Strategies include reversal or withholding of anticoagulation (AC) and neurosurgical (NSG) interventions. The consequences of these decisions can significantly impact both short- and long-term survival. Currently no guidelines on management exist. We reviewed medical and NSG practices and subsequent outcomes at a single academic center. Methods: We retrospectively identified all patients within our institutional LVAD database who developed ICH between 2012-2018. Demographic, clinical, and outcome data were analyzed. Results: Of 283 LVAD patients, 32 (11%) had 34 ICHs: 16 intraparenchymal (IPH, 47%), 4 subdural (SDH, 12%), and 14 subarachnoid (SAH, 41%). IPH occurred sooner than other subtypes (median 138 [48 - 258]) days post-LVAD placement vs SDH (431 [22 - 915] days) and SAH (484 [272 - 990] days). Mean GCS was 12.9 (3.7). All patients were on AC with a mean INR of 3.3 (range 1.2 - 7.0). AC was reversed in 27 (79%) patients, most frequently with a combination of Vit K (56%), FFP (47%), or PCC (26%). AC was held in 31 patients a median of 4 (2.0 - 9.0) days; 1 thrombotic event occurred while off AC (spinal cord infarct). After AC resumption, 16 thrombotic events occurred a median of 15 (8.0-37.0) days post-ICH and led to death in most (79%) by 6 months. Five patients underwent NSG intervention: 1 hemicraniectomy, 3 EVDs, and 1 aneurysm coiling. Six patients (18%) went on to receive heart transplant. Overall, 30-day mortality was 26%. IPH had the highest 30-day mortality (38% vs SDH, 0% and SAH, 29%). At 6 months, overall mortality was 44%. Conclusion: ICH is a common post-LVAD complication with high short- and long-term mortality. Of the subtypes, IPH was the most common, most deadly and occurred the earliest following LVAD placement. At our institution, most patients underwent AC reversal but AC was also resumed rapidly. Delayed thrombotic complications nearly doubled 6-month mortality. The development of ICH did not preclude successful heart transplant. Further research in the care of LVAD patients with ICH may help improve these short- and long-term outcomes.